A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Inclusion Criteria:

Patients with a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC disease not amenable to surgery with curative intent
Not received more than 2 prior systemic therapies- one of which must have been a platinum based regimen- for primary or recurrent disease
Tissue submitted for HRG-biomarker testing
ECOG performance status (PS) of 0 or 1

Exclusion Criteria:

Known ALK mutation
Presence of exon 19 deletion or exon 21 (L858R) substitution of the EGFR gene
Received >2 prior systemic anti-cancer drug regimen for locally advanced disease
Prior treatment with an anti-ErbB3 antibody
CTCAE grade 3 or higher peripheral neuropathy
Symptomatic CNS metastases or CNS metastases requiring steroids
Any other active malignancy requiring systemic therapy
Clinically significant cardiac disease